NCT07219992 Parent-Based Treatment for Adolescent Anxiety
| NCT ID | NCT07219992 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Anxiety Disorder of Adolescence |
| Study Type | INTERVENTIONAL |
| Enrollment | 108 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2028-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 108 participants in total. It began in 2025-11-01 with a primary completion date of 2028-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to test the efficacy of a parent-only approach to treating anxiety disorders in adolescents: SPACE (Supportive Parenting for Anxious Childhood Emotions). The comparator is another parent-based approach, PES (Parent Education and Support). The study design is a randomized controlled trial with 2 treatment arms and 3 assessment points (pre, post, and follow-up) using questionnaire data and clinical interviews.
Eligibility Criteria
Inclusion Criteria: * Meet criteria for a primary DSM-5 AD, including separation anxiety disorder, social anxiety disorder, generalized anxiety disorder, specific phobia, panic disorder, and agoraphobia (determined by the ADIS-C/P). * Cease all other psychosocial treatment, upon consultation with the project staff and service provider. * Not currently use any psychotropic medication, other than a stable dose (i.e., same dose for a minimum of 6 months prior to enrollment; no changes during course of the study) of a stimulant medication or selective serotonin reuptake inhibitor (SSRI). * Have an eligible and willing participating parent (see parent exclusions below). Exclusion Criteria: Adolescent: * Meet criteria for any DSM-5 disorder more impairing than the most impairing AD (determined by the ADIS-C/P). * Have any of the following disorders: autism spectrum disorder; intellectual disability; neurocognitive disorders; bipolar disorder; schizophrenia and other psychotic disorders; and alcohol and substance use disorders (determined by the Health History Form and ADIS-C/P). * Report a suicide attempt in the last 3 months, or current suicide intent and plans (determined by the ASQ). * Be a victim of past or present undisclosed abuse requiring investigation or ongoing supervision by the Department of Social Services. * Not have sufficient proficiency with the English language to complete assessments. Parents: * Have any of the following: intellectual disability; neurocognitive disorders; untreated bipolar disorder; untreated schizophrenia and other psychotic disorders; and untreated alcohol and substance use disorders (determined by the Health History Form). * Not be living with the adolescent at least 50% of the time for at least one year prior to enrollment. * Not have sufficient proficiency with the English language to complete assessments and treatment.
Contact & Investigator
Rebecca Etkin, PhD
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT07219992 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 17 Years, studying Anxiety Disorder of Adolescence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07219992 currently recruiting?
Yes, NCT07219992 is actively recruiting participants. Contact the research team at Rebecca.etkin@yale.edu for enrollment information.
Where is the NCT07219992 trial being conducted?
This trial is being conducted at New Haven, United States.
Who is sponsoring the NCT07219992 clinical trial?
NCT07219992 is sponsored by Yale University. The principal investigator is Rebecca Etkin, PhD at Yale University. The trial plans to enroll 108 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.